Ii-Key-GP100-TYR

Ii-Key-GP100-TYR is an investigational **peptide cancer vaccine** designed for melanoma immunotherapy. It appears to be part of the Ii-Key platform developed by NuGenerex Immuno-Oncology, in which the invariant-chain derived Ii-Key motif is linked to melanoma-associated antigenic peptide epitopes to enhance **MHC class II loading** and thereby amplify **CD4-positive T-helper cell priming** and downstream antitumor immune responses. Based on the name and the surrounding Ii-Key literature, this construct is intended to target melanoma differentiation antigens including **gp100** and **tyrosinase**, with the goal of inducing helper T-cell responses that support broader cellular immunity against melanoma. Publicly available evidence indicates that a melanoma trial was being planned, but clear evidence of late-stage clinical development, regulatory approval, or commercial launch was not identified.

Other names

Ii-Key gp100 Tyr peptide vaccineIi-Key/gp100 Tyr hybrid peptide vaccine